Table 2.
CYP27B1 Gene Expression | |||
---|---|---|---|
Variables | B | 95% C.I. | p -Value |
HIV infection | −0.301 | −0.4932; −0.110 | 0.002 |
Gender | 0.116 | −0.022; 0.254 | 0.098 |
Age | 0.001 | −0.007; 0.006 | 0.899 |
25(OH)D3 levels | 0.002 | 0.000; 0.005 | 0.072 |
Time since HIV diagnosis # | 0.001 | −0.001; 0.002 | 0.283 |
TNF-α gene expression | |||
HIV infection | 0.622 | 0.403; 0.842 | 0.000 |
Gender | 0.075 | −0.084; 0.233 | 0.355 |
Age | 0.004 | −0.003; 0.011 | 0.279 |
25(OH)D3 levels | −0.003 | −0.006; −0.001 | 0.022 |
Time since HIV diagnosis # | 0.001 | −0.001; 0.002 | 0.546 |
IFN-γ gene expression | |||
HIV infection | 0.606 | 0.313; 0.900 | 0.000 |
Gender | 0.040 | −0.171; 0.252 | 0.709 |
Age | −0.006 | −0.016; 0.003 | 0.210 |
25(OH)D3 levels | −0.005 | −0.008; −0.001 | 0.018 |
Time since HIV diagnosis # | −0.002 | −0.005; 0.002 | 0.983 |
LC3 gene expression | |||
HIV infection | −0.280 | −0.499; −0.060 | 0.012 |
Gender | −0.024 | −0.182; 0.134 | 0.763 |
Age | 0.001 | −0.006; 0.008 | 0.745 |
25(OH)D3 levels | 0.002 | −0.001; 0.005 | 0.176 |
Time since HIV diagnosis # | 0.001 | −0.001; 0.002 | 0.477 |
ATG5 gene expression | |||
HIV infection | −0.334 | −0.525; −0.143 | 0.001 |
Gender | 0.086 | −0.051; 0.224 | 0.218 |
Age | 0.005 | −0.001; 0.011 | 0.105 |
25(OH)D3 levels | 0.003 | 0.001; 0.005 | 0.019 |
Time since HIV diagnosis # | −0.001 | −0.003; 0.001 | 0.729 |
BECN1 gene expression | |||
HIV infection | −0.168 | −0.451; 0.0115 | 0.245 |
Gender | −0.092 | −0.296; 0.113 | 0.379 |
Age | 0.006 | −0.003; 0.016 | 0.178 |
25(OH)D3 levels | 0.002 | −0.001; 0.006 | 0.263 |
Time since HIV diagnosis # | −0.001 | −0.002; 0.002 | 0.874 |
TGM2 gene expression | |||
HIV infection | 0.025 | −0.158; 0.209 | 0.787 |
Gender | −0.007 | −0.139; 0.125 | 0.916 |
Age | 0.002 | −0.004; 0.008 | 0.490 |
25(OH)D3 levels | −0.003 | −0.006; −0.001 | 0.005 |
Time since HIV diagnosis # | −0.002 | −0.003; 0.001 | 0.925 |
Bold font for p-values indicates statistically significant differences at a level ≤ 0.05. # This variable has only been tested on HIV+ subjects.